Targeted therapeutics for inner ear disorders
Encased in the densest bone in the body and shielded by the blood-labyrinth barrier, the inner ear has resisted drug therapy for decades.Spiral is changing that.
There is no FDA-approved treatment for Ménière's disease
600K+Americans living with Ménière's
50MUS adults with measurable hearing loss
Hearing loss is one of the largest modifiable risk factors for dementia.Lancet Commission, 2024

The problem
Inner ear diseases have treatable biology but almost no approved drugs
90%
of inner ear disorders involve inflammation or neurodegeneration, biology that drugs can target.
Devices
improve hearing but don't treat the underlying disease.
Off-label
steroids are the default treatment, though they were never developed or approved for the ear.
Our platform
MICS™ and our local formulations
Ophthalmology changed when drugs could be delivered straight to the eye. We are bringing that approach to the ear: local formulations delivered to the inner ear with MICS™ (Minimally Invasive Cochlear System).
One platform across anti-inflammatory, otoprotective and neuroprotective drugs.
Explore the platformPrecision
Each formulation is placed where it needs to act, under direct visualization.
Versatility
Formulations matched to each drug substance, from small molecules to biologics.
In clinic
Designed for the ENT office, not the operating room.
Pipeline
See the full pipeline
A platform-enabled portfolio
Programs advancing across hearing loss and balance disorders.
Program
Discovery
Preclinical
Phase 1
Phase 2/3
Next
SPT-2101
Ménière's disease
Dexamethasone otic suspension
2027 US IND clearance
The product
SPT-2101 is an investigational dexamethasone otic suspension that forms a crosslinked hydrogel at the round window membrane. It is placed under direct visualization with MICS™ (Minimally Invasive Cochlear System), by intratympanic administration in the clinic under local anesthesia.
Learn about Ménière's diseaseClinical data
70%of patients had complete resolution of definitive vertigo days at three months after a single administration, the study's primary endpoint. Phase 1b/2a, four sites in Australia, with no serious adverse events.
View trial registration (ANZCTR)What's next
US IND clearance in 2027, followed by a registrational trial with a design informed by our analysis of prior Ménière's programs. Sudden hearing loss follows as a second indication in Europe.
SPT-2101
Sudden hearing loss
SPT-2101 second indication
2027 EU CTA clearance
SPT-4106
Cochlear synaptopathy
Local neuroprotectant
2027 Australia FIH
SPT-5108
Cisplatin ototoxicity
Local cisplatin chelator
Partner-supported
Completed / active
Planned / next
Built on MICS™
Our people
Meet the team
Built by category leaders
Our team combines drug-delivery expertise with deep otology and clinical-development experience.

Hugo PerisFounder & CEO

Charles Limb, MDChief Medical Officer

Kyle PetersonChief Financial Officer

Alex SeelenbergerChief Business Officer

Anna StepanenkoChief Technical Officer
Board of Directors
Eugene de Juan, MDExecutive Chairman
Hugo PerisFounder & CEO
Anthony Adamis, MDIndependent
Angela MacfarlaneIndependent
Nawal OuzrenIndependent
Jean-Frédéric PaulsenFerring Ventures SA
Guy Jean SavoirSavoir Capital
Diamantis Xylas, MDCatalio Capital
Warren ThalerGund Investment
News
See all news
Latest news
Press release
Spiral Therapeutics Announces $27 Million Series B Financing and Strategic Partnership with Advanced Bionics
Advanced Bionics and a major global pharmaceutical company join Spiral's Series B financing as new strategic investors, with Gund Investment leading the round and continued participation from Ferring Ventures, Uni-Bio Science Group and other existing investors. R&D collaboration combines Advanced Bionics' global leadership in cochlear implant technology with Spiral's expertise in developing novel therapeutics for inner ear disorders. Proceeds from the transactions will support the development of Spiral's...
Read more